Statin Discontinuation in Older Adults: Safety and Clinical Implications
The STREAM trial evaluates the impact of stopping primary prevention statins in patients over 70.
1The STREAM Trial Overview
The STREAM trial, published in the New England Journal of Medicine, investigated the effects of discontinuing statins in 1,880 patients aged 70 or older. Participants had at least two chronic conditions and were using statins for primary prevention. The study, conducted from 2021 to 2025, utilized an open-label, non-inferiority design.
2Primary Outcome Results
Discontinuing statins met the trial's primary endpoint for non-inferiority regarding event-free survival time. Patients who stopped therapy averaged 96.5 weeks of event-free survival, compared to 98.5 weeks for those who continued. While statistically non-inferior, the results did not demonstrate a clear clinical advantage for stopping the medication in this population.
3Cardiovascular Event Trends
Despite the non-inferiority finding, cardiovascular events trended higher in the discontinuation group at 10.7% versus 8.2% for those continuing treatment. Over a median follow-up of 103 weeks, events reached 12.7% in the discontinuation group. Data suggests one additional cardiovascular event occurred for every 40 individuals who stopped their statin therapy.
4Quality of Life Metrics
The study assessed patient-centered secondary outcomes including pain, falls, and sarcopenia to determine if stopping statins improved daily well-being. Results showed no significant difference between the two groups, undermining arguments that statin withdrawal would improve quality of life. Stopping the medication did not alleviate common physical complaints among the elderly.
5Biological and Clinical Context
Researchers noted that biological mechanisms, such as endothelial dysfunction and prothrombotic pathways, might explain the increased cardiovascular risk observed after stopping statins. At 12 months, LDL cholesterol levels rose significantly to 176.0 mg/dL in the discontinuation group, compared to 99.4 mg/dL for those who maintained their prescribed statin regimen.
6Subgroup Data Analysis
Nicolas Rodondi, MD, noted that discontinuation appeared disproportionately safer for specific subgroups, including individuals with diabetes and those recruited from primary care settings rather than hospitals. These findings suggest that the decision to deprescribe should be highly individualized, considering the patient's overall health status and specific chronic condition profile.
7Shared Decision-Making Importance
Experts emphasize that older adults represent a heterogeneous group, with 15% to 18% having no coronary artery calcium. Because many patients face competing health risks, the decision to continue or stop statins requires a context-based approach. Clinicians are encouraged to engage in shared decision-making, weighing individual life expectancy and health priorities.
8Future Research Requirements
The STREAM investigators acknowledged limitations, including the lack of blinding and substantial crossovers during the trial. They concluded that while deprescribing appears generally acceptable, further randomized trials are necessary. Future studies must assess the impact of other cardiovascular preventive medications to ensure results are not biased by concurrent medical interventions.